Grifols, S.A. (NASDAQ:GRFS - Get Free Report) shares saw unusually-strong trading volume on Wednesday . Approximately 1,401,980 shares were traded during trading, an increase of 8% from the previous session's volume of 1,298,023 shares.The stock last traded at $7.68 and had previously closed at $7.73.
Analysts Set New Price Targets
Separately, Morgan Stanley began coverage on Grifols in a report on Wednesday, February 12th. They set an "overweight" rating on the stock.
Check Out Our Latest Research Report on GRFS
Grifols Price Performance
The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The firm has a market cap of $5.49 billion, a P/E ratio of 6.82 and a beta of 0.35. The company has a 50-day moving average of $7.50 and a 200 day moving average of $8.13.
Hedge Funds Weigh In On Grifols
Hedge funds and other institutional investors have recently modified their holdings of the stock. R Squared Ltd bought a new position in shares of Grifols during the 4th quarter worth approximately $28,000. GAMMA Investing LLC raised its position in Grifols by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 1,527 shares during the last quarter. Blue Trust Inc. raised its position in Grifols by 254.0% in the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 4,970 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Grifols by 354.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 6,335 shares during the last quarter. Finally, First Trust Advisors LP bought a new position in Grifols in the 4th quarter valued at $75,000.
Grifols Company Profile
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Further Reading
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
